...order winners of the operational strategy of Pfizer Inc. Worlds’ leading pharmaceutical manufacturer A report prepared by Dr Amit Roy Contents 1.0 Executive Summary 4 2.0 Background 5 3.0 Key Financial information 5 4.0 Order Qualifiers and Order Winners 6 4.0.1 Safe clinical trials and drug delivery methods to objects 6 4.0.2 Health and safety standards 7 4.0.3 License to manufacture 7 4.0.4 Off license manufacturing 7 4.0.5 License to distribute the products in a specific regions 7 4.0.6 Quality of products 7 4.0.7 Cost 8 4.0.8 Supply chain 8 4.0.9 Capacity 8 4.0.10 Innovation 8 4.0.11 Market offering 9 4.0.12 Human resources 9 4.0 Pfizer’s broad order winners and operational strategy 9 4.1.13 Improving the Performance of the Innovative Core 9 4.1.14 Engine for Sustainable Innovation 10 4.1.15 Making the Right Capital Allocation Decisions 14 4.1.16 Earning Respect from Society 15 4.1.17 Creating an Ownership Culture 16 4.1.18 Corporate Governance 17 5.0 Conclusion 17 6.0 References 18 1.0 Executive Summary This report investigates the operational strategy of Pfizer, world’s leading pharmaceutical company in terms...
Words: 3580 - Pages: 15
...Pharmaceutical Supply Chain Abstract • The global pharmaceutical supply chain is very complex and critical to a $650 billion dollar value industry which ensures the world population has necessary medicines. • Manufacturers have the responsibility to produce sufficient quantities of drugs to meet a growing global demand while maintaining quality to ensure safety. • Global and local regulatory agencies around the world have a daunting task to monitor manufacturers, raw material suppliers, and stem counterfeit pharmaceutical production. • Wholesale distributors, importers, and retail pharmacies have a large amount of power in the supply chain as they pull the demand from the manufacturers and provide the medicines to end-consumers. • In a changing industry where there are fewer blockbuster drugs and increasing use of generic offerings, manufacturers as well as participants at all levels of the supply chain must look for areas to improve efficiencies to be profitable in the long-run. Pharmaceutical Supply Chain Analysis 2 Introduction A transparent and efficient pharmaceutical supply chain contributes significantly towards improving the availability of essential medications. The reality across the world is that pharmaceutical supply and distribution consists of different stakeholders from both the public and private sectors to create complex systems. In a heavily regulated field, globalization has placed increasing demands on regulatory agencies to ensure the safety and...
Words: 6177 - Pages: 25
...vertical chain of a major pharmaceutical company as well as TCE and its effect on make or buy decision. The vertical chain is ‘’ the process that begins with the acquisition of raw materials and ends with the distribution and sale of finished goods and service.’’ (Besanko et al, 2010, p119) The term vertical integration is used to describe firms that produce and sell their goods without relying on external co-ordination. Firm’s vertical boundaries can identify what to make (internally inside the organization) and what to buy (externally by using the market). Some of the pharmaceutical companies like Pfizer have strong vertical chains. So as to market its drugs in 150 countries, it gives high importance for production that starts by acquiring active pharmaceutical ingredients (API) and shifting them to manufacturing sites all across the globe. These manufacturing sites are either approved under the stringent laws of FDA or EMEA (2 important bodies responsible in monitoring the quality of registered products across the globe). Sometimes Pfizer also uses loan-licensing companies as external manufacturers when in-house facilities are not available or feasible. Once the product is manufactured, it is sent for quality control release and then packed and shipped to the first point of distribution (global hubs). From these locations; depending on the demand from each region; packed products (formulated products) move to the regional hubs. These hubs in turn will supply to either...
Words: 1815 - Pages: 8
...S.W.O.T analysis for Pfizer Strengths 1. Pfizer's presence in more than 50 countries and one of the largest research based pharmaceutical company globally. 2. Pfizer's is having excellent facilities for R&D to create innovative and breakthrough products 3. M & A with big pharma brands increased Pfizer's brand reputation. (Annual Review, 2013) Weakness 1. Limited scope for growth due to tough competition from other major pharma brands 2. Dependence on Key In-Line Products such as Lyrica, Celebrex , Lipitor, Viagra etc., 3. Pfizer follows global policy throughout its group companies (Annual Review, 2013) Opportunities 1. Synergy by entering strategic agreements with other research or pharmaceutical companies to boost its research 2. Increasing global awareness about healthcare needs 3. Emerging markets through mergers and acquisitions (Form 10K, 2013) Threats 1. Competition from generic drug manufactures is major challenge world wide 2. Increased government regulations and price constraints 3. Counterfeit medicine which appears to be the same as an authentic Pfizer medicine. (Form 10K, 2013) Key Success factors of Pfizer 1. Product development. as per the Pfizer announcement in early 2014 on financial results there are 7 products are in Phase 3 development stage those are Palbociclib, Dacomitinib, ALO-02, Tafamidis, Bococizumab (RN316), Ertugliflozin, Tanezuma for treatment of several diseases (Financial Report, 2013) 2. Capital allocation and expenses...
Words: 441 - Pages: 2
...New Product Launch Plan in the market By Pfizer Pharmaceutical Ltd Company In the year of 2014 in the United States of America. Overview: As the CEO of the Pfizer Pharmaceuticals Ltd, I would like to represent our new product launch plan that includes our company background, new drug information, new product launch plan, estimated costs of the projected plan, market analysis, contractual issues, evaluation, risk management staff and the general approaches etc. I would like to say our new product called as a DuaveeTM which was made by the Wyeth Pharmaceuticals which is wholly-owned subsidiary of our company Pfizer pharmaceutical Ltd and it is also a part of broader research collaboration with Ligand Pharmaceutical incorporated. We are going to plan this product in the market next year 2014. All the information related to launch schedules and estimated costs also included in the project. Our company project includes mainly six elements and we will focus mainly on these six types of elements such as: Project Definition: Objectives: According to me, it is the best success of the company for achievement in the fields of the Women’s medicines. Main objectives of the company are that our company will get more profit by launching the new product and we also will get new reputation in the market. Before launching this product we must have to understand what is the product contains? And how it will help? So here I want to describe something about the product that is need to...
Words: 1826 - Pages: 8
...Elwood Leftridge Professor Joanne Land Kazlauskas GPS-4278W 05-01-2013 Putting It All Together a Look at Pfizer Pharmaceutical Company Pfizer Pharmaceutical Company is not only the world’s largest research pharmaceutical company in the world, but also the leader of technological advances. This organization has been in operation for over 160 successful years, and has over 117,000 diverse workers employed worldwide from all facets of life. It is important to employ a solid employee workforce within an organization, this can either make or break an organization. “In 2012 Pfizer was ranked #40 among Fortune 500 with 2011 revenue totaling almost 68 million dollars, and a profit margin of over 10 million dollars”(CNN Money, 2013). The purpose of this paper is to break apart Pfizer into four different organizational perspectives, analyze them, and then put them back together again. Or as with the title of the textbook (Reframing Organizations: Artistry, Choice, and Leadership. Vol. 4) suggests to reframe organizations to a particular frame or frames. The frames that I will be using to analyze Pfizer Pharmaceuticals will be the Structural Frame, the Symbolic Frame, the Human Resources Frame, as well the Political Frame. To begin, I will describe the Pfizer organization using Bolman & Deal’s Structural Frame perspective. The structural components that I will discuss will be the Division of Labor, the Leadership Structure, and Roles and Responsibilities of the organization...
Words: 5349 - Pages: 22
...Cracks in the Pharmaceutical Supply Chain http://www.cio.com/article/print/16565 Print Article Close Window From: www.cio.com Cracks in the Pharmaceutical Supply Chain – Susannah Patton, CIO January 15, 2006 As an undercover agent with the Drug Enforcement Administration and the Food and Drug Administration, Aaron Graham saw firsthand how counterfeit drugs can slip into the pharmaceutical supply chain. Graham, now VP and chief security officer for Purdue Pharma, once posed as the manager of an "institutional pharmacy" selling drugs at a discount to secondary wholesalers who were then supposed to sell them to nursing homes. Soon after he began, his phone started ringing. Dozens of smaller pharmaceutical wholesale companies were calling, desperate to buy his drugs. These secondary or "gray market" wholesalers scour the country and the world for low-price drugs they can sell back to major wholesalers for a profit. In addition to trawling for institutional pharmacies, some secondary wholesalers have been known to purchase counterfeit drugs from criminal organizations in places such as China, Thailand or Colombia. Graham, who was part of a two-year FDA sting operation known as "operation gray pill," helped expose a system in which large and small wholesalers were taking advantage of multitiered pricing in the industry. Prescription drugs are sold at discounts to subsidized groups such as nursing homes and also exported at lower prices. Graham and his colleagues found...
Words: 3359 - Pages: 14
...Supply and Demand Pharmaceutical companies are generating billions of dollars in revenues on prescription drugs that have patent protection. Once a drug loses its patent protection, other manufacturers are allowed to make a generic form of the drug. Having a generic form of a brand name drug available should increase the supply in the market for consumers by driving cost down. This paper will discuss the effect of generic drugs and evaluate their effect on the supply and demand for drugs that no longer have patent protection. An example of a prescription drug that recently lost its patent is Lipitor. It is a cholesterol-lowering drug. It has been a top selling drug for several years, totaling over seven billion dollars in sales in the US and a combined total of over ten billion dollars worldwide in 2010. Lipitor’s patent expired on November 30, 2011 making the drug available to be manufactured as a generic drug, therefore increasing affordability to consumers. Until May 2012, Ranbaxy had the sole rights for creating Lipitor’s generic form after the patent expired; after that, it was made available to other drug companies. Pfizer continued to market Lipitor after its patent expired and had spent over eighty seven million dollars in marketing, to generate three hundred eighty three million dollars in the first quarter of 2012. Market power shifted from Pfizer to other drug manufacturers with the expiration of the patent (Hughes, 2012). When a brand name prescription...
Words: 1447 - Pages: 6
...Introduction of Pfizer Pfizer is an American multinational pharmaceutical corporation that headquartered in New York City [Pfizer. Retrieved on April 3, 2010] and with its research headquarters in Groton, Connecticut and United States. It is one of the world's largest pharmaceutical companies by revenues.[Bloomberg Businessweek. 27 March 2012. Retrieved 8 July 2012] Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines that includes immunology, oncology, cardiology, diabetology/endocrinology, and neurology. It owns the cholesterol - lowering drug Lipitor, which brings in approximately quarter of its revenue and was the best-selling medicine in the world in 2009. Pfizer founded in 1849 by Charles Pfizer . The company started its activities in the pharmaceutical industry throughout the world with many companies, including acquisitions and mergers like Warner - Lambert in 2000 Farmsya in 2003 and White in 2009, noted that the company's cost of $ 68 billion in achieved in 2009.[ http://www.nytimes.com/2009/01/26/business/26drug.html] 1- External analysis PESTLE is part of companies’ external analysis and is a part of companies’ strategic analysis (Political Legal Economical Environmental Social Technological analysis).It helps in understanding the companies’ external factors which influence the development of the company. 1.1- Political and legal : In healthcare system and pharmaceutical industry the political factors...
Words: 2504 - Pages: 11
...www.pwc.com/pharma2020 Pharma 2020: Supplying the future Which path will you take? Pharmaceuticals and Life Sciences Previous publications in this series include: Pharmaceuticals Pharma 2020: The vision Which path will you take?* Published in June 2007, this paper highlights a number of issues that will have a major bearing on the industry by 2020. The publication outlines the changes we believe will best help pharmaceutical companies realise the potential the future holds to enhance the value they provide to shareholders and society alike. Pharmaceuticals and Life Sciences Pharma 2020: Challenging business models Which path will you take? Fourth in the Pharma 2020 series and published in April 2009, this report highlights how Pharma’s fully integrated business models may not be the best option for the pharma industry in 2020; more creative collaboration models may be more attractive. This paper also evaluates the advantages and disadvantages of the alternative business models and how each stands up against the challenges facing the industry. *connectedthinking Pharma 2020: The vision # Pharmaceuticals and Life Sciences Pharma 2020: Virtual R&D Which path will you take? This report, published in June 2008, explores opportunities to improve the R&D process. It proposes that new technologies will enable the adoption of virtual R&D; and by operating in a more connected world the industry, in collaboration with researchers, governments, healthcare payers and providers...
Words: 13197 - Pages: 53
...ETHICAL CULTURAL ANALYSIS: Pfizer Incorporated Prepared by Benjamin Smith Submitted in partial fulfillment of Thomas Edison State College course: 2014AUG PHI-384-GS004: Ethics and the Business Professional. October 23, 2014 [pic] Introduction Pfizer is the second-largest biopharmaceutical company in the world, and largest research-based company in the world (Herper 2014). They are the producers of some of the most popular names in prescription drugs, including Lipitor®, Viagra®, Xanax®, and Zoloft®. They are also one of the leading names of over the counter drugs and supplements such as Advil®, Centrum®, and Robitussin®. Pfizer employs over 78,000 personnel all over the world in most every continent. Its operations encompass researching and development of new medications, vaccines, and therapies; government regulatory compliance; and providing care and support for global healthcare programs. My interest in Pfizer is that I plan on changing careers into the medical field as a physician or research scientist. As the leading research-based pharmaceutical company, I would aspire to work with neuroscientist Dr. Michael Ehlers and his team. This analysis will review Pfizer Incorporated as a responsible, ethical company by analyzing its mission statements, core values, published principles, and code of ethics, how these are reflected in their actions and which ethical concepts are displayed in these actions; how Pfizer prevents and responds to problematic...
Words: 4047 - Pages: 17
...Johnson and Johnson Supply Chain Case Analysis Table of Contents I. Executive Summary…………………………………….3 II. Backgound / History……………………………………4 III. Supply Chain Analysis…………………………………5 IV. Recommendations………………………………………7 V. Work Cited………………………………………………8 I. Executive Summary Johnson and Johnson is a medical devices, pharmaceutical and consumer packaged goods manufacture founded in 1886. They are U.S. multinational company, who is listed among the Fortune 500. Johnson and Johnson Credo is a statement of their values and responsibilities that was written over 60 years ago. It articulates their responsibilities to customers, employees, communities and shareholders. There philosophy and core values are centered and desired to provide the safest and most reliable products and services to their customers. Johnson and Johnson offer’s a diverse business. A business that is a leader and offers many medical devices, pharmaceutical and consumer packaged goods that dominate over their competitor’s. There forecast show’s growth despite them facing challenges. They have successfully employed strategies to differentiate themselves that helps them distinguish themselves from its competitors. Johnson and Johnson does not have control over external supply chain, but are committed to ensure operations on their behalf are consistent with their values. With an annual spending being about $30 billion, they are able to leverage their purchasing power and set expectation...
Words: 1300 - Pages: 6
...9-707-441 REV: MARCH 30, 2010 TARUN KHANNA KRISHNA PALEPU CLAUDINE MADRAS Teva Pharmaceutical Industries, Ltd In Israel we have a 1970s song based on a poem from 1953 by Amir Gilboa about Theodor Herzl.1 It has a line in it about Herzl: “Suddenly a man rises in the morning, feels he is a people, and starts walking.” That is exactly what Hurvitz did. Suddenly he woke up in the morning, feels he is a giant world class company, and starts walking. No one, aside from Herzl, has accomplished anything as remotely as impressive in this country as Hurvitz. It was impossible, a million to one odds at best, and he still did it. He woke up one morning and started walking. — Ori Hershkovitz, equity analyst at Tel Aviv-based Leader & Company The markets had not been kind to Teva Pharmaceutical during the first half of 2006. The stock had plunged nearly 30% from January 1 to June 30, erasing billions of dollars from the company’s market capitalization. Even good news, such as reports in July of Teva’s wildly successful introduction of generic Zocor—the largest blockbuster drug ever to go off-patent—had failed to boost the stock significantly. Since nearly every retirement fund and mutual fund in Israel invested in Teva, this drop had been felt throughout the population, in effect amounting to every Israeli family losing NIS 3000, or $675.1 Teva was more than the world’s leading producer of generic pharmaceuticals (see Exhibit 1 for financials). It represented the gold standard of business...
Words: 12524 - Pages: 51
...Report analyzes the US pharmaceutical industry Report analyzes the US pharmaceutical industry Published on April 9, 2010 at 12:04 PM Research and Markets (http://www.researchandmarkets.com/research/eded8d/pharmaceutical_ind) has announced the addition of the "Pharmaceutical Industry in the United States" report to their offering. Over the past decade, pharmaceutical companies have pushed the scientific envelope, working at the cellular and molecular levels to dramatically advance the treatment of disease. Between 1995 and 2005, more than 300 new drugs, biologics, and vaccines that prevent and treat over 150 conditions were approved by the FDA. The FDA also gave the go-ahead for numerous new indications for previously approved medicines, allowing physicians to tailor treatment strategies to meet a patients individual disease status, past medication history, side effect tolerance, and preferences. The US pharmaceutical industry is a highly globalized industry, dominated by multinational companies that engage in significant business activity in many countries and whose products are distributed and marketed worldwide. The industry has undergone dramatic structural changes over the past few decades, with the rise of the biotechnology sector, substantial growth in demand driven by demographics and substitution away from other therapeutic modalities such as surgery, and increased competition from globally active generic manufacturers. The pharmaceutical industry is under mounting...
Words: 643 - Pages: 3
...pharmaceutical background and actually being a part of a multinational pharmaceutical company in the gulf, we are focusing on the Gulf region as the main target area for our research. We had 2 interviews from the company, one is a sales manager in one of the gulf countries (Qatar), and the other one is the Logistics co-coordinator and supply chain manager (Dubai) for the gulf region, but actually due to the sensitive information and the company policy they preferred not to disclose their identities on the research. The interviews were done collectively then the answers are demonstrated under their respective sections of the research. The research demonstrates that ABBOTT Gulf is lacking any manufacturing facility or internal distribution system, so focusing mainly on the selling process and its support functions like finance, HR and marketing. Also there’s no such position as the operations manager and each function is being managed by the director and any chances for improvements are being feed backed and being modified after encountering the problem. A sort of corrective approach than a preventive one. Supply chain management Since supply chain management involves all the movements in delivering the products to end customer and Abbott operates in the gulf without a manufacturing facility or...
Words: 4945 - Pages: 20
